Next Article in Journal
Cellular microRNAs Repress Vesicular Stomatitis Virus but Not Theiler’s Virus Replication
Previous Article in Journal
Molecular Mechanisms of HTLV-1 Cell-to-Cell Transmission
Article Menu

Export Article

Open AccessArticle
Viruses 2016, 8(3), 78; doi:10.3390/v8030078

A Novel Vaccine Approach for Chagas Disease Using Rare Adenovirus Serotype 48 Vectors

1
Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA
2
Division of Pulmonary, Allergy and Critical Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA
3
Center for AIDS Research, University of Alabama at Birmingham, Birmingham, AL 35294, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Curt Hagedorn
Received: 10 November 2015 / Revised: 26 February 2016 / Accepted: 3 March 2016 / Published: 10 March 2016
(This article belongs to the Section Antivirals & Vaccines)
View Full-Text   |   Download PDF [2934 KB, uploaded 10 March 2016]   |  

Abstract

Due to the increasing amount of people afflicted worldwide with Chagas disease and an increasing prevalence in the United States, there is a greater need to develop a safe and effective vaccine for this neglected disease. Adenovirus serotype 5 (Ad5) is the most common adenovirus vector used for gene therapy and vaccine approaches, but its efficacy is limited by preexisting vector immunity in humans resulting from natural infections. Therefore, we have employed rare serotype adenovirus 48 (Ad48) as an alternative choice for adenovirus/Chagas vaccine therapy. In this study, we modified Ad5 and Ad48 vectors to contain T. cruzi’s amastigote surface protein 2 (ASP-2) in the adenoviral early gene. We also modified Ad5 and Ad48 vectors to utilize the “Antigen Capsid-Incorporation” strategy by adding T. cruzi epitopes to protein IX (pIX). Mice that were immunized with the modified vectors were able to elicit T. cruzi-specific humoral and cellular responses. This study indicates that Ad48-modified vectors function comparable to or even premium to Ad5-modified vectors. This study provides novel data demonstrating that Ad48 can be used as a potential adenovirus vaccine vector against Chagas disease. View Full-Text
Keywords: adenovirus serotype 48; antigen capsid-incorporation; amastigote surface protein-2; gp83; Chagas’ disease; vaccine; Trypanosoma cruzi adenovirus serotype 48; antigen capsid-incorporation; amastigote surface protein-2; gp83; Chagas’ disease; vaccine; Trypanosoma cruzi
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Farrow, A.L.; Peng, B.J.; Gu, L.; Krendelchtchikov, A.; Matthews, Q.L. A Novel Vaccine Approach for Chagas Disease Using Rare Adenovirus Serotype 48 Vectors. Viruses 2016, 8, 78.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top